Gonadotropin-releasing hormone analogues for dysfunctional bleeding in women after liver transplantation: a new application
| Autor: | Joseph M. Brandes, Zeev Blumenfeld, Yaacov Baruch, Rafael Enat |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
medicine.medical_specialty Uterine fibroids medicine.medical_treatment Gonadotropin-releasing hormone Gonadotropin-Releasing Hormone Postoperative Complications Internal medicine medicine Humans Precocious puberty Triptorelin Pamoate business.industry Pituitary tumors Obstetrics and Gynecology Metrorrhagia medicine.disease female genital diseases and pregnancy complications Liver Transplantation Menstruation Polycystic ovarian disease Transplantation Endocrinology Reproductive Medicine Female Ovulation induction Uterine Hemorrhage medicine.symptom business |
| Zdroj: | Fertility and Sterility. 57:1121-1123 |
| ISSN: | 0015-0282 |
| Popis: | A new clinical indication for GnRH agonists treatment seems to exist in addition to the many indications known so far (4, 5). These previously mentioned indications include: uterine fibroids, precocious puberty, endometriosis, polycystic ovarian disease, ovulation induction for assisted fertilization (in vitro or in vivo), treatment of various tumors such as prostatic, breast, pancreatic, ovarian, and pituitary tumors, and various catamenial disorders such as premenstrual syndrome and porphyria. Women after liver transplantation, who are in the reproductive age and who experience menometrorrhagia or dysfunctional bleeding, seem to be a new indication for application of these useful GnRH analogues. This application may prevent the potential hepatotoxicity or cholestasis of E-P combinations usually used for treatment of dysfunctional bleeding. The recommended treatment is of relatively short duration (3 to 6 months), within the first 2 years of the transplantation, after which a more prolonged treatment should be considered. This treatment may also spare the need for contraception during its administration because both oral contraceptives and intrauterine device are relatively contraindicated in these patients (the latter because of the immunocompromised state). We believe this application to become more common because of increasing numbers of liver transplantations and improved survival rate. It may be looked at as a "new application of a relatively new drug for a new and enlarging situation." |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|